Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
38 hedge funds and large institutions have $2.67M invested in Oncternal Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 14 closing their positions.
13% less call options, than puts
Call options by funds: $47K | Put options by funds: $54K
24% less funds holding
Funds holding: 50 → 38 (-12)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
57% less capital invested
Capital invested by funds: $6.23M → $2.67M (-$3.56M)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$75.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59K |
| 3 |
RIM
Reliant Investment Management
Memphis,
Tennessee
|
+$22.1K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$20.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$221K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$156K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$155K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$108K |
| 5 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$104K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| – | -$3.2K | -2 | Closed |
|
|
BRWA
52
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$1.3K | -1 | Closed |
|
53
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1K | – | – |
|
ONCT Hedge Fund Activity: Q3 2014 in Review
38 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2014, worth a combined $2.67M — down 57% from $6.23M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ONCT and 2 opened new positions — a net loss of 12 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was BlackRock Institutional Trust, adding an estimated $75.2K. The largest seller was Northern Trust, cutting an estimated $221K.
- 38 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2014, down from 50 in Q2 2014.
- Funds reported $2.67M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2014, down 57% quarter-over-quarter.
- 2 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2014 and 14 closed out, a net change of -12 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2014 was BlackRock Institutional Trust, an estimated $75.2K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2014 was Northern Trust, an estimated $221K sold.
Based on aggregated 13F filings for Q3 2014.